Literature DB >> 16183340

Determination of cryptotanshinone and its metabolite in rat plasma by liquid chromatography-tandem mass spectrometry.

M Song1, T J Hang, Zh X Zhang, R Du, J Chen.   

Abstract

A sensitive and selective LC-MS-MS method has been developed and validated for the determination of cryptotanshinone (CTS) and its active metabolite tanshinone II A (TS II A) in rat plasma using fenofibrate (FOFB) as internal standard. Liquid-liquid extraction was used for sample preparation. Chromatographic separation was achieved on a Waters symmetry ODS column using methanol and water (85:15) as mobile phase delivered at 1.0 mL/min. LC-MS-MS analysis was carried out on a Finnigan LC-TSQ Quantum mass spectrometer using atmospheric pressure chemical ionization (APCI) and positive multiple reaction monitoring. Ions monitored were m/z 297.0--> 251.0 for CTS, m/z 295.0--> 249.0 for TS II A, and m/z 361.1--> 233.0 for FOFB with argon at a pressure of 0.2 Pa and collision energy of 25 eV for collision-induced dissociation (CID). The assay was linear over the range 0.1-20 ng/mL for CTS and 0.2-15 ng/mL for TS II A. The average recoveries of CTS and TS II A from rat plasma were 93.7 and 94.7%, respectively. The established method has been applied in a pharmacokinetic study of CTS in rats.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16183340     DOI: 10.1016/j.jchromb.2005.09.014

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  8 in total

Review 1.  The conduct of drug metabolism studies considered good practice (I): analytical systems and in vivo studies.

Authors:  Xiaodong Liu; Lee Jia
Journal:  Curr Drug Metab       Date:  2007-12       Impact factor: 3.731

2.  Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles.

Authors:  LianDong Hu; Qianbin Xing; Jian Meng; Chuang Shang
Journal:  AAPS PharmSciTech       Date:  2010-03-30       Impact factor: 3.246

3.  Charactering the metabolism of cryptotanshinone by human P450 enzymes and uridine diphosphate glucuronosyltransferases in vitro.

Authors:  Jin Zeng; Yu-Juan Fan; Bo Tan; Hui-Zong Su; Yue Li; Lin-Lin Zhang; Jian Jiang; Fu-Rong Qiu
Journal:  Acta Pharmacol Sin       Date:  2018-02-08       Impact factor: 6.150

4.  Tanshinones inhibit the growth of breast cancer cells through epigenetic modification of Aurora A expression and function.

Authors:  Yi Gong; Yanli Li; Hamid M Abdolmaleky; Linglin Li; Jin-Rong Zhou
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

5.  Bioavailability and pharmacokinetic comparison of tanshinones between two formulations of Salvia miltiorrhiza in healthy volunteers.

Authors:  Lu Xing; Zhi-Rong Tan; Jin-Le Cheng; Wei-Hua Huang; Wei Zhang; Wen Deng; Chun-Su Yuan; Hong-Hao Zhou
Journal:  Sci Rep       Date:  2017-07-05       Impact factor: 4.379

6.  Development of cryptotanshinone-loaded pellets for angina chronotherapy: In vitro/in vivo prediction and evaluation.

Authors:  Zhenghua Li; Shuangshuang Zhang; Hongxiang Yan; Jianping Liu
Journal:  Asian J Pharm Sci       Date:  2018-03-12       Impact factor: 6.598

Review 7.  Tanshinones: sources, pharmacokinetics and anti-cancer activities.

Authors:  Yong Zhang; Peixin Jiang; Min Ye; Sung-Hoon Kim; Cheng Jiang; Junxuan Lü
Journal:  Int J Mol Sci       Date:  2012-10-22       Impact factor: 5.923

8.  Pharmacokinetics and tissue distribution study of tanshinone IIA after oral administration of Bushen Huoxue Qubi granules to rats with blood stasis syndrome.

Authors:  Yuanqing Wang; Jianye Yan; Shunxiang Li; Xiong Cai; Wei Wang; Kun Luo; Dan Huang; Jiesheng Gao
Journal:  Pharmacogn Mag       Date:  2014-07       Impact factor: 1.085

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.